GCG and fatty liver disease: Moreover, our conclusion is based on trials using not only the change in hepatic enzymes as the end‐point but also hepatic steatosis, inflammation and fibrosis as outcome measures, providing more comprehensive evidence of the efficacy of GLP‐1 RAs in the treatment of NAFLD than previous studies.